Racemic Ketamine as an Alternative to Electroconvulsive Therapy for Unipolar Depression: A Randomized, Open-Label, Non-Inferiority Trial (KetECT)
Open accessThe DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Abstract
Background: Ketamine has emerged as a fast-acting and powerful antidepressant, but no head to head trial has been performed, Here, ketamine is compared with electroconvulsive therapy (ECT), the most effective therapy for depression. Methods: Hospitalized patients with unipolar depression were randomized (1:1) to thrice-weekly racemic ketamine (0.5 mg/kg) infusions or ECT in a parallel, open-label, non-inferiority study. The primary outcome was remission (Montgomery Åsberg Depression Rating Scale score ≤10). Secondary outcomes included adverse events (AEs), time to remission, and relapse. Treatment sessions (maximum of 12) were administered until remission or maximal effect was achieved. Remitters were followed for 12 months after the final treatment session. Results: In total 186 inpatients were included and received treatment. Among patients receiving ECT, 63% remitted compared with 46% receiving ketamine infusions (P = .026; difference 95% CI 2%, 30%). Both ketamine and ECT required a median of 6 treatment sessions to induce remission. Distinct AEs were associated with each treatment. Serious and long-lasting AEs, including cases of persisting amnesia, were more common with ECT, while treatment-emergent AEs led to more dropouts in the ketamine group. Among remitters, 70% and 63%, with 57 and 61 median days in remission, relapsed within 12 months in the ketamine and ECT groups, respectively (P = .52). Conclusion: Remission and cumulative symptom reduction following multiple racemic ketamine infusions in severely ill patients (age 18–85 years) in an authentic clinical setting suggest that ketamine, despite being inferior to ECT, can be a safe and valuable tool in treating unipolar depression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“For instance, one trial found that remission rates post-ketamine were inferior to those post-ECT [69]”
From Ketamine in neuropsychiatric disorders: an update (2024) · cites this paper as [69]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A new depression scale designed to be sensitive to change
Montgomery, S. A., & Åsberg, M. (1979) · British Journal of Psychiatry · doi:10.1192/bjp.134.4.382 · Cited by 13,962 · cited 2×
“Hospitalized patients, aged 18–85 years, diagnosed with unipolar depression according to the DSM-IV with a score of ≥20 on the Montgomery–Åsberg Depression Rating Scale (MADRS)(Montgomery and Asberg 1979) were informed about an ongoing study comparing ECT with a new experimental treatment.”
MethodThe Brief Psychiatric Rating Scale.
Overall, J. E., & Gorham, D. R. (1962) · Psychological Reports · doi:10.2466/pr0.1962.10.3.799 · Cited by 11,090 · cited 1×
“To quantify treatment-emergent psychotic or dissociative symptoms, we used a modified Brief Psychiatric Rating Scale (Overall JE, 1962), comprising items 7–11, 14–15, 20, 22–24, and the Clinician Administered Dissociative States Scale (Bremner et al., 1998).”
MethodRush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.11.1905 · Cited by 5,643
Antidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856 · cited 3×
“The reports of a glutamate-modulating drug that alleviated depressive symptoms, causing patients to remit within hours after 1 i.v. subanaesthetic dose, received enormous attention(Berman et al., 2000; Zarate et al., 2006).”
BackgroundA randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766
The Epidemiology of Depression Across Cultures
Kessler, R. C., & Bromet, E. J. (2013) · Annual Review of Public Health · doi:10.1146/annurev-publhealth-031912-114409 · Cited by 2,657 · cited 2×
“Depression is a debilitating disorder affecting millions globally (Kessler and Bromet 2013), causing severe suffering and reduced life expectancy due to associated somatic co-morbidities and elevated suicide risk (Laursen et al., 2016).”
BackgroundMurray, C. J. L., Barber, R. M., Foreman, K. J., Ozgoren, A. A., Abd-Allah, F., Abera, S. F., Aboyans, V., Abraham, J. P., Abubakar, I., Abu-Raddad, L. J., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)61340-x · Cited by 1,964 · cited 1×
“The burden on society is immense, and depression is a leading contributor to disability-adjusted life years(DALYs et al., 2015).”
Interval estimation for the difference between independent proportions: comparison of eleven methods
Newcombe, R. G. (1998) · Statistics in Medicine · doi:10.1002/(sici)1097-0258(19980430)17:8<873::aid-sim779>3.0.co;2-i · Cited by 1,851 · cited 1×
“The 95% confidence interval of the difference between remission rates was calculated according to Newcombe(Newcombe, 1998).”
MethodBremner, J. D., Krystal, J. H., Putnam, F. W., Southwick, S. M., Marmar, C., Charney, D. S., & Mazure, C. M. (1998) · Journal of Traumatic Stress · doi:10.1023/a:1024465317902 · Cited by 817 · cited 2×
“Aggregated Clinician Administered Dissociative States Scale and Brief Psychiatric Rating Scale scores were significantly higher in the ketamine group 1 hour after the first treatment ( P = .01), but not at other time points.”
MethodMurrough, J. W., Perez, A. M., Pillemer, S., Stern, J., Parides, M. K., aan het Rot, M., Collins, K. A., Mathew, S. J., Charney, D. S., & Iosifescu, D. V. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.06.022 · Cited by 786 · cited 2×
“Similar concerns have been raised about ketamine as patients were reported to relapse within 1 (Murrough et al., 2013; Ghasemi et al., 2014; Shiroma et al., 2014; Singh et al., 2016); Vande Voort et al., 2016); Cusin et al., 2017; Feifel et al., 2017; Perez-Esparza et al., 2018; Vidal et al., 2018)…”
Background
Cited by
Ketamine versus ECT for Nonpsychotic Treatment-Resistant Major Depression
Anand, A., Mathew, S. J., Sanacora, G., Murrough, J. W., Goes, F. S., Altinay, M., Aloysi, A. S., Asghar-Ali, A. A., Barnett, B. S., Chang, L. C., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2302399 · Cited by 276
Ketamine Treatment for Depression: A Review
Yavi, M., Lee, H., Henter, I. D., Park, L. T., & Zarate, C. A. (2022) · Discover Mental Health · doi:10.1007/s44192-022-00012-3 · Cited by 161
Rhee, T. G., Shim, S. R., Forester, B. P., Nierenberg, A. A., McIntyre, R. S., Papakostas, G. I., Krystal, J. H., Sanacora, G., & Wilkinson, S. T. (2022) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2022.3352 · Cited by 141
Ketamine in neuropsychiatric disorders: an update
Johnston, J. N., Kadriu, B., Kraus, C., Henter, I. D., & Zarate, C. A. (2024) · Neuropsychopharmacology · doi:10.1038/s41386-023-01632-1 · Cited by 108
“For instance, one trial found that remission rates post-ketamine were inferior to those post-ECT [69], and a meta-analysis comparing ECT and ketamine obtained similar results, demonstrating an inferiority of ketamine to ECT [70].”
ResultScott, F., Hampsey, E., Gnanapragasam, S., Carter, B., Marwood, L., Taylor, R. W., Emre, C., Korotkova, L., Martín-Dombrowski, J., Cleare, A. J., et al. (2023) · Journal of Psychopharmacology · doi:10.1177/02698811221104058 · Cited by 87
“However, more recent investigations of ketamine have been more promising, with 30% remaining in remission after 12 months (with a median duration until relapse of 61 days) in one study (Ekstrand et al., 2021).”
BackgroundKaster, T. S., Blumberger, D. M., Gomes, T., Sutradhar, R., Wijeysundera, D. N., & Vigod, S. N. (2021) · The Lancet Psychiatry · doi:10.1016/s2215-0366(22)00077-3 · Cited by 70
Saelens, J., Gramser, A., Watzal, V., Zarate, C. A., Lanzenberger, R., & Kraus, C. (2025) · Neuropsychopharmacology · doi:10.1038/s41386-024-02044-5 · Cited by 51
Ketamine vs Electroconvulsive Therapy for Major Depressive Episode
Menon, V., Varadharajan, N., Faheem, A., & Andrade, C. (2023) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2023.0562 · Cited by 50
Nygren, A., Reutfors, J., Brandt, L., Bodén, R., Nordenskjöld, A., & Tiger, M. (2023) · BJPsych Open · doi:10.1192/bjo.2023.5 · Cited by 49
Self-citationSeizure Duration and Electroconvulsive Therapy in Major Depressive Disorder
Gillving, C., Ekman, C. J., Hammar, Å., Landén, M., Lundberg, J., Movahed, P., Nordanskog, P., von Knorring, L., & Nordenskjöld, A. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.22738 · Cited by 55
Self-citationA response to yet another defence of ECT in the absence of robust efficacy and safety evidence
Read, J. (2022) · Epidemiology and Psychiatric Sciences · doi:10.1017/s2045796021000846 · Cited by 42
Ketamine and Electroconvulsive Therapy for Treatment-Refractory Depression
Huang, X., & Zheng, W. (2023) · ALPHA PSYCHIATRY · doi:10.5152/alphapsychiatry.2023.231358 · Cited by 39
“It is important to note that this particular RCT 6 focused exclusively on patients suffering from TRD without psychosis, distinguishing it from a recent European trial 15 and the previous meta-analysis.”
ResultGarel, N., Drury, J., Lévesque, J. T., Goyette, N., Lehmann, A., Looper, K. J., Erritzøe, D., Dames, S., Turecki, G., Rej, S., et al. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1268832 · Cited by 40
“Lastly, ketamine’s acute psychoactive effects may cause distress—ranging from mild discomfort to acute panic attacks leading to premature treatment termination (79).”
BackgroundRecent advances in electroconvulsive therapy in clinical practice and research
Mukhtar, F., Regenold, W. T., & Lisanby, S. H. (2023) · Faculty Reviews · doi:10.12703/r/12-13 · Cited by 40
Moreira, D. D. A. S., Gauer, L. E., Teixeira, G., da Silva, A. C. F., Cavalcanti, S., & Quevedo, J. (2023) · Journal of Affective Disorders · doi:10.1016/j.jad.2023.02.152 · Cited by 30
Kritzer, M. D., Pae, C., & Masand, P. S. (2022) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2022.2069749 · Cited by 23
“adverse effects on cognition or the need for general anesthesia [89].”
Ketamine for Depression—Knowns, Unknowns, Possibilities, Barriers, and Opportunities
Andrade, C. (2023) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2023.3982 · Cited by 20
Ketamine or ECT? What Have We Learned From the KetECT and ELEKT-D Trials?
Ekstrand, J., Takamiya, A., Nordenskjöld, A., Kirov, G., Sienaert, P. A., Kellner, C. H., & Movahed, P. (2023) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyad065 · Cited by 23
“However, we acknowledge that this factor alone had limited impact, as given that the prevalence of psychotic depression in naturalistic cohorts typically ranges between 15% and 20% (Johnson et al., 1991; Ohayon and Schatzberg, 2002; Ekstrand et al., 2022).”
BackgroundSelf-citationJelovac, A., McCaffrey, C., Terao, M., Shanahan, E., Whooley, E., McDonagh, K., McDonogh, S., Loughran, O., Shackleton, E., Igoe, A., et al. (2025) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2025.3019 · Cited by 25
Petrucci, A. B. C., Fernandes, J. V. A., Reis, I. A., da Silva, G. H. S., RECLA, B. M. F., de Mendonça, J. C., Pedro, V. C. S., d’Assunção, L. E. N., & Valiengo, L. D. C. L. (2024) · Psychiatry Research · doi:10.1016/j.psychres.2024.115994 · Cited by 21
Rask, O., Nordenskjöld, A., Johansson, B. A., & Movahed, P. (2022) · European Child & Adolescent Psychiatry · doi:10.1007/s00787-022-02123-2 · Cited by 18
“Transient memory impairment is a well-known phenomenon and has been demonstrated in several studies [29, 30].”
ResultSelf-citationWang, N., Zhu, S., Chen, S., Zou, J., Zeng, P., & Tan, S. (2025) · Reviews in the Neurosciences · doi:10.1515/revneuro-2024-0147 · Cited by 12
Guo, H., Tang, L., He, M., Tang, W., Liu, J., Wu, S., Yuan, S., Wang, J., & Tang, X. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1681060 · Cited by 16
Therapeutic Protocols Using Ketamine and Esketamine for Depressive Disorders: A Systematic Review
FREIND, J. M. K., Beserra, F. R., Menezes, B. S., & Mograbi, D. C. (2023) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2023.2248989 · Cited by 13
New and emerging pharmacologic treatments for MDD
Uyar, A., & Gönül, A. S. (2025) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2025.1621887 · Cited by 20
New insights into the mechanisms of electroconvulsive therapy in treatment-resistant depression
Ruiz, A. C., Haseeb, A., Baumgartner, W., Leung, E., Scaini, G., & Quevedo, J. (2025) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2025.1614076 · Cited by 20
Bloomfield, A., Chan, N. W., Fryml, L. D., Horace, R. W., & Pyati, S. (2023) · Current Pain and Headache Reports · doi:10.1007/s11916-023-01150-1 · Cited by 16
Electroconvulsive Therapy and Its New Competitors
Zilles‐Wegner, D., Kellner, C. H., & Sartorius, A. (2024) · Journal of Ect · doi:10.1097/yct.0000000000001034 · Cited by 10
Hussain, S., Gale, C. K., Sarma, S., Smith, J. P., Bayes, A. J., & Loo, C. K. A. (2025) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/00048674251333577 · Cited by 11
Liu, Y., Yang, J., & Liu, Y. (2024) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2024.05.022 · Cited by 12
Esketamine Nasal Spray in Major Depressive Disorder: A Meta‐Analysis of Randomized Controlled Trials
Wang, Z., Jiang, L., Ma, W., Li, X., Gao, Q., Lian, S., & Yu, W. (2025) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.3555 · Cited by 15
Ketamine versus ECT for Nonpsychotic Treatment-Resistant Major Depression
Souza, S. A., Josino, T. R., & Bisol, L. W. (2023) · New England Journal of Medicine · doi:10.1056/nejmc2308757 · Cited by 12
Ultrabrief pulse electroconvulsive therapy for depression: a systematic review and meta-analysis
Jelovac, A., & McLoughlin, D. M. (2025) · Molecular Psychiatry · doi:10.1038/s41380-025-03327-z · Cited by 9
Petrozzi, B. P., Spangemacher, M., Deicher, A., Drews, L., Defert, J., Silva-Colmenero, A. Y., Wein, P., Riedinger, E., Gründer, G., Gilles, M., et al. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2024.1415505 · Cited by 12
Mathew, S. J., Jha, M. K., & Anand, A. (2023) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2023.3979 · Cited by 8
Arnison, T., Rask, O., Nordenskjöld, A., & Movahed, P. (2023) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.13623 · Cited by 9
“27,28 Although the present study cannot rule out the possibility that other complications may be associated with ECT, such as aspiration pneumonia, sustained seizures, or allergic reactions to anesthetic agents, such types of adverse events were not reported in the data and have rarely been…”
Self-citationShi, Z.-M., Lan, X.-J., Chen, Q., Chen, J., Su, Z. Z., Huang, X., Ning, Y.-P., Yang, X.-H., Wei, X., & Zheng, W. (2024) · Journal of Affective Disorders · doi:10.1016/j.jad.2024.11.034 · Cited by 9
Barruel, D., Belnou, P., Plaze, M., & Masson, V. D. (2025) · Psychiatry Research · doi:10.1016/j.psychres.2025.116738 · Cited by 7
Clinical and biological markers of electroconvulsive therapy effectiveness: a narrative review
Zilles‐Wegner, D., von Mücke-Heim, I.-A., Yrondi, A., & Takamiya, A. (2026) · Translational Psychiatry · doi:10.1038/s41398-026-03900-2 · Cited by 10
“The KetECT study [15] included patients with psychotic symptoms and found a signi fi cant superiority of ECT.”
A synopsis of multitarget therapeutic effects of anesthetics on depression
Wu, G., & Xu, H. (2023) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2023.176032 · Cited by 7
Perspectives in treatment-resistant depression: esketamine and electroconvulsive therapy
Baldinger, P., Spies, M., Bozic, I., Kasper, S. F., Rujescu, D., & Frey, R. (2024) · Wiener klinische Wochenschrift · doi:10.1007/s00508-024-02358-w · Cited by 9
Juneja, K., Afroze, S., Goti, Z., Sahu, S., Asawa, S., Bhuchakra, H. P., Natarajan, B., & Pandey, S. (2024) · Discover Mental Health · doi:10.1007/s44192-024-00077-2 · Cited by 7
Gałecki, P., Bliźniewska-Kowalska, K. M., Cubała, W. J., Depukat, A., Mosiołek, A., RYBAKOWSKI, J. K., Samochowiec, J., Sobolewski, B., Szulc, A., & Dudek, D. (2024) · Psychiatria Polska · doi:10.12740/pp/189494 · Cited by 12
“Table 1 summarizes studies on the effectiveness of ketamine both as a stand-alone treatment (monotherapy) and in combination with other treatments [9, 26, 29, 32, 34-51].”
IsHak, W. W., Meyer, A., Freire, L., Totlani, J., Murphy, N., Renteria, S., Salem, M., Chang, T., Abdelsalam, R., Khan, R., et al. (2024) · PubMed Central · Cited by 8
Jelovac, A., McCaffrey, C., Terao, M., Shanahan, E., Mohamed, E., Whooley, E., McDonagh, K., McDonogh, S., Igoe, A., Loughran, O., et al. (2023) · BMC Psychiatry · doi:10.1186/s12888-023-05365-9 · Cited by 7
“More recently, randomised trials have compared serial ketamine infusions to active comparators midazolam [15] and electroconvulsive therapy (ECT) [16, 17].”
BackgroundResultTorre, J. T. L., Gallo, J., Mahammadli, M., Zalewa, D., & Williams, M. T. (2024) · Journal of Psychedelic Studies · doi:10.1556/2054.2024.00348 · Cited by 11
Case report: Adult with bipolar disorder and autism treated with ketamine assisted psychotherapy
Harris, C. P., Jones, B., Walker, K. L., & Berry, M. S. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2024.1322679 · Cited by 9
Uppinkudru, C., Pathak, H., Raj Kumar, K., Bridgit, S., Bagali, K. B., Pantoji, M., Ezhumalai, N., Parlikar, R. U., Shah, V., Balachander, S., et al. (2024) · Psychiatry Research · doi:10.1016/j.psychres.2024.115839 · Cited by 6
Tamman, A. J. F., Anand, A., & Mathew, S. J. (2022) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2022.2049754 · Cited by 6
“more favorably to ECT compared with younger patients [100].”
BackgroundTreatment-resistant depression in children and adolescents
Chang, J.-C., Hai-Ti-Lin, Wang, Y.-C., & Gau, S. S. (2023) · Progress in brain research · doi:10.1016/bs.pbr.2023.03.004 · Cited by 7
Combination of ketamine and electroconvulsive therapy in treatment resistant depression
Kendirlioglu, B. K., Özmen, M., Uluçay, S., Bayrak, T., Erturan, E. S., Salkım, Ö., Tunç, A. E. B., Çelik, H. E. A., & Küçükgöncü, S. (2025) · Journal of Affective Disorders · doi:10.1016/j.jad.2025.04.017 · Cited by 6
Reif, A., Anıl, Y. A., Bitter, I., Buyze, J., Frey, R., Fu, D. J., Godinov, Y., Haggström, L., Kambarov, Y., Nielsen, R., et al. (2026) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2026.112801 · Cited by 4
Ma, Z., Wu, F., & Zheng, W. (2025) · Psychiatric Quarterly · doi:10.1007/s11126-025-10121-1 · Cited by 8
“Ultimately, six randomized controlled trials evaluated the efficacy and safety of ketamine versus ECT were meeting our inclusion criteria [ 8, 9 , 25 – 28 ].”
Terao, I., Tsuge, T., Sato, T., Endo, K., Kotake, K., Banno, M., & Kataoka, Y. (2025) · Psychiatry and Clinical Neurosciences Reports · doi:10.1002/pcn5.70136 · Cited by 10
Kavakbasi, E., Rosemann, K., Yilmaz, M., Berndt, H., & Baune, B. T. (2025) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-025-02041-9 · Cited by 4
“[10].”
Stavrum, A.-K., Sirignano, L., Frid, L. M., Frank, J., Foo, J. C., Spíndola, L., Höffler, K. D., Oedegaard, K. J., Haavik, J., Rietschel, M., et al. (2025) · Translational Psychiatry · doi:10.1038/s41398-025-03772-y · Cited by 4
Gao, Y., Wang, S., Li, T., Guo, X., Lu, Z., Luo, R., Yang, B., & Cao, J. (2025) · Journal of Affective Disorders · doi:10.1016/j.jad.2025.03.005 · Cited by 4
A long, strange trip: Ketamine treatment in psychiatry
Nutt, D. J., Morgan, C. J. A., Erritzøe, D., Greenway, K. T., & Young, A. H. (2025) · Journal of Psychopharmacology · doi:10.1177/02698811251379393 · Cited by 5
Considering New and Emerging Treatment Strategies for Depression: Beyond STAR*D and the Monoamines
McInnes, L. A., & Marton, T. F. (2024) · Current Psychiatry Research and Reviews · doi:10.2174/0126660822284575240130053259 · Cited by 4
Sandström, K., Kampman, O., & Asellus, P. (2024) · Acta Neuropsychiatrica · doi:10.1017/neu.2024.18 · Cited by 3
Persson, M., Fabri, V., Reijbrandt, A., Lexén, A., Eriksson, H., & Movahed, P. (2025) · PLoS ONE · doi:10.1371/journal.pone.0316339 · Cited by 3
Self-citationCoerts, D. T., Veraart, J. K. E., Kamphuis, J., Smith-Apeldoorn, S. Y., Schoevers, R. A., & van Belkum, S. M. (2025) · Journal of Ect · doi:10.1097/yct.0000000000001103 · Cited by 2
Ketamine Versus Electroconvulsive Therapy for the Treatment of Depression: A Guide for Clinicians
Elliott, S. I., Katz, R. B., Ostroff, R. B., Ansari, M., Holmes, S. E., & Sanacora, G. (2025) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.20240040 · Cited by 2
He, G., Xi, M., Zhang, T., Wang, S., & Liu, G. (2025) · Journal of Pharmaceutical Analysis · doi:10.1016/j.jpha.2025.101378 · Cited by 2
“Ket, as a rapidly acting antidepressant, has gained increasing attention in recent years for the treatment of mental disorders [30].”
Li, K. J., Slama, N. E., Chen, I. L., Ridout, S. J., & Iturralde, E. (2025) · Psychiatry Research · doi:10.1016/j.psychres.2025.116647 · Cited by 2
(Es)ketamine as a treatment for depressive episodes with psychotic features: systematic review
Santos, H. C., Rodrigues, A., Machado, T. L. G. N., Gonçalves‐Pinho, M., Young, A. H., & Juruena, M. F. (2025) · BJPsych Open · doi:10.1192/bjo.2025.10830 · Cited by 1
“47 Mischel et al 39 and Trejos Orozco et al 42 did not use instruments to assess depressive symptoms, and only Ga ł uszko-W¸egielnik et al 33 and Ekstrand et al. 41 assessed psychotic symptoms objectively (although the latter did not provide scores for the subgroup of patients with psychotic symptoms).”
InfluentialKetamine versus ECT for major depression: flawed evidence base
Braithwaite, R., Jelovac, A., Kellner, C. H., Sartorius, A., Sienaert, P. A., & McLoughlin, D. M. (2025) · The Lancet Psychiatry · doi:10.1016/s2215-0366(25)00300-1 · Cited by 2
Nikolin, S., Massaneda‐Tuneu, C., Brettell, L., & Loo, C. K. A. (2026) · Translational Psychiatry · doi:10.1038/s41398-026-03806-z · Cited by 4
“In our analysis, RCTs with larger sample sizes [13, 14], and therefore reduced susceptibility to random fl uctuations at baseline, showed smaller differences (SMD = − 0·23; and SMD = − 0·05).”
InfluentialChaudhri, S., Amin, A., Panjiyar, B. K., Al-taie, D. S., AlEdani, E. M., Gurramkonda, J., & Hamid, P. (2024) · Cureus · doi:10.7759/cureus.55596 · Cited by 5
“To conclude, the studies by Ghasemi et al. [12], Kheirabadi et al. [13], Ekstrand et al. [14], Sharma et al. [15], Basso et al. [16], and Allen et al. [17] offer diverse insights into ketamine and ECT for TRD.”
BackgroundResultSpangemacher, M., Karl, S., Aksay, S. S., Lamadé, E. K., Plemper, J., Sartorius, A., & Petrozzi, B. P. (2024) · Biomarkers in Neuropsychiatry · doi:10.1016/j.bionps.2024.100115 · Cited by 2
Arora, S. K., Praveen, A. P., Subu, O., Suhas, S., Gowda, G. S., Reddi, V. S. K., & John, J. P. (2025) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2025.104383 · Cited by 2
Gao, K. (2024) · Medicina · doi:10.3390/medicina60060936 · Cited by 4
“Our case also demonstrated challenges and highlighted the unmet need in the treatment of TRBPD.”
BackgroundBeyond surgery: Repurposing anesthetics for treatment of central nervous system disorders
Mielko, J., Pakulska, J., Oszczyk, A., Lustyk, K., Pytka, K., & Sałaciak, K. (2025) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2025.111386 · Cited by 1
Neuropharmacology of Ketamine and Its Use in the Treatment of Major Depressive Disorder: A Review
Papadopoulos, Z. (2025) · Cureus · doi:10.7759/cureus.83244 · Cited by 3
“ECT involves inducing controlled epileptic seizures by passing current through an electrode attached to the skull [3].”
InfluentialMyerson, J., Rufino, K. A., Mathew, S. J., Fletcher, M., Puri, N., & Oh, H. (2025) · Journal of Affective Disorders · doi:10.1016/j.jad.2025.119727 · Cited by 2
History of episodic heavy alcohol use predicts antidepressant effectiveness of ketamine
Raquib, A. R., Nguyen, V. T., Brown, J. C., Sedgewick, A. E., Seiner, S. J., Taylor, J. J., Siddiqi, S., & Meisner, R. C. (2025) · Psychopharmacology · doi:10.1007/s00213-025-06918-4 · Cited by 2
“These results may assist in patient selection for ECT vs ketamine.”
Song, G., & Ugwah-Oguejiofor, C. J. (2025) · International Journal of Psychiatry in Clinical Practice · doi:10.1080/13651501.2025.2576205 · Cited by 2
“…Manual of Mental Disorders, Fifth Edition (DSM-5) diagnostic criteria, while most other clinical trials adopted the DSM-4 diagnostic criteria for including patients (Allen et al., 2015; Anand et al., 2023; Basso et al., 2020; Ekstrand et al., 2022; Ghasemi et al., 2014; Sharma et al., 2020).”
InfluentialAdvancing ketamine in the treatment hierarchy for refractory depression: commentary, Jelovac et al
Jelovac, A., Braithwaite, R., & McLoughlin, D. M. (2025) · The British Journal of Psychiatry · doi:10.1192/bjp.2025.10472 · Cited by 1
Regen, F. (2026) · Springer eBooks · doi:10.1007/978-3-662-72452-1_1 · Cited by 1
Ketamin und Esketamin: Antidepressive pharmakologische Effekte und augmentierte Psychotherapie
Schüle, C., Koller, G., & Herwig, U. (2024) · Nervenheilkunde · doi:10.1055/a-2309-6457 · Cited by 1
“In den beiden Zulassungsstudien für intranasales Esketamin in einer Notfallindikation bei mittelgradig oder schwer depressiven Patienten mit konkreten Suizidgedanken, ASPIRE-1 bei erwachsenen Patienten mit einer mittelgradigen bis schweren Episode einer Major Depression als akute Kurzzeitbehandlung zur schnellen Reduk…”
BackgroundIntersections of Anesthesiology and Psychiatry: Comment
Sartorius, A., Karl, S., Janke, C., & Beck, G. C. (2025) · Anesthesiology · doi:10.1097/aln.0000000000005310 · Cited by 1
Ketamine versus electroconvulsive therapy for major depressive disorder: A deeper dive into the data
Wang, Z., Chiang, C.-H., Hsia, Y. P., Chiang, C., & Chiang, C. (2023) · Journal of Affective Disorders · doi:10.1016/j.jad.2023.10.116 · Cited by 1
Reproducing the Psychedelic Experience: “One of the 5 Most Meaningful Experiences in Life”?Preprint
Kajonius, P., & Sjöström, D. (2023) · PsyArXiv (OSF Preprints) · doi:10.31234/osf.io/m6pqj · Cited by 1
Prediction is easy; change is hard
Price, L. H. (2022) · The Brown University Psychopharmacology Update · doi:10.1002/pu.30868
Glue, P., & McNaughton, N. (2023) · Psychiatry Research Case Reports · doi:10.1016/j.psycr.2023.100137
Juneja, K., Afroze, S., Goti, Z., Sahu, S., Asawa, S., Priya, B. H., Natarajan, B., & Pandey, S. (2023) · Research Square · doi:10.21203/rs.3.rs-3374935/v1
Loosening the Shackles of Depression
McShane, R. H. (2023) · New England Journal of Medicine · doi:10.1056/nejme2309758
Janski, A. M., Hristidis, V. C., Zorumski, C. F., & Conway, C. R. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-95702-1.00064-6
Gauer, L. E., Cavalcanti, S., Moreira, D. D. A. S., Teixeira, G., & Quevedo, J. (2024) · Journal of Affective Disorders · doi:10.1016/j.jad.2023.12.085
Pham, G. S., & Mathew, S. J. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-18496-3.00014-8
Saldanha, G. G., Locatelli, L., & Miozzo, I. A. (2024) · Physiology International · doi:10.1556/2060.2024.00410
Shire, N. G., Ioannou, M., Falk, Ö., Wold, A. B., Wass, C., Szabó, Z., & Steingrímsson, S. (2024) · Journal of Affective Disorders Reports · doi:10.1016/j.jadr.2024.100870 · Cited by 1
KET or ECT for treatment-resistant depression?
Spies, M., Kasper, S. F., Frey, R., & Baldinger, P. (2024) · International Journal of Psychiatry in Clinical Practice · doi:10.1080/13651501.2025.2462725 · Cited by 1
“…did not match the findings of a very similarly designed european randomised controlled trial comparing intravenous ketamine and eCt (KeteCt trial (ekstrand et al., 2022)) in tRD, which deemed eCt superior. the marked disparities in outcome parameters in both studies were subject of a recent…”
Ketamine for unipolar major depression: critical examination of antidepressant effects
Patel, A. (2025) · BJPsych Advances · doi:10.1192/bja.2024.84
Treatment-Resistant Depression: The Role of Electroconvulsive Therapy
Kupis, M., Paszkowska, M., Znamirowska, P., Mularczyk, K., Karaban, Ł., Jakubiak, A., Miśkiewicz, J., Borawski, M., Ciuła, A., & Kuźnieców, T. (2025) · Quality in Sport · doi:10.12775/qs.2025.41.60326
“The main categories of antidepressants include selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), and monoamine oxidase inhibitors (MAOIs) [10].”
InfluentialMovahed, P., & Takamiya, A. (2025) · Neuromethods · doi:10.1007/978-1-0716-4599-4_16
Electroconvulsive Therapy Versus Ketamine in Suicidality: A Systematic Review of Randomized Trials
Grover, S., Naskar, C., & Niyogi, S. G. (2025) · Current Behavioral Neuroscience Reports · doi:10.1007/s40473-025-00311-3
“…indication of the efficacy of ketamine therapy in reducing suicidality and suicidal ideation is shown in the large trial by Ekstrand et al. [20] They com - pared ECT ( n = 91) and ketamine ( n = 95) and reported 6 sui - cide attempts, including 1 successful one in the ECT group, and 4…”
Therapieresistenz bei Depression braucht neue Antworten
Seifritz, E. (2025) · DNP – Die Neurologie & Psychiatrie · doi:10.1007/s15202-025-6542-6
Intermittent Ketamine and Neuromodulation Treatment Evoke Synergistic Antidepressant-Relevant Action
Brown, K. A., & Gould, T. D. (2025) · Biological Psychiatry · doi:10.1016/j.biopsych.2025.10.009 · Cited by 1
“After nearly a century of clinical use, electroconvulsive therapy (ECT) remains the most effective antidepressant, including in cases of treatment resistance (7–9) [although evidence suggests that ketamine may be equally effective in subpopulations (10)].”
Intranasal esketamine for depression: Transforming psychiatric treatment or a temporary solution?
Cartas, N., Dăscălescu, I., Neaga, A., Păun, M. L., & Petriuc, A. F. (2025) · Bulletin of Integrative Psychiatry · doi:10.36219/bpi.2025.3.07
Metadata
- Authors
- Ekstrand, J., Fattah, C., Persson, M., Cheng, T., Nordanskog, P., Åkeson, J., Tingström, A., Lindström, M. B., Nordenskjöld, A., & Movahed Rad, P.
- Affiliations
- Lund University (SE)
- Linköping University (SE)
- Örebro University (SE)
- Department of Clinical Sciences, Faculty of Medicine, Lund University , Lund , Sweden
- ORCID
- Venue
- International Journal of Neuropsychopharmacology
- Publisher
- Oxford University Press (OUP)
- Published
- 2021-12-04
- Volume
- 25
- Issue
- 5
- Pages
- 339-349
- ISSN
- 1461-1457 (ISSN-L)
- 1469-5111
- PMC
- PMC9154276
- OpenAlex
- W4206656872
- Cited by
- 113
- References
- 36
- Citations by year
- 2026: 14 · 2025: 39 · 2024: 27 · 2023: 24 · 2022: 9
- FWCI
- 8.75
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- The International Journal of Neuropsychopharmacology (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- DiVA (Linkoping University) (submittedVersion, other-oa)
- Lund University Publications (Lund University) (submittedVersion)
- Funders
- Swedish Research Council (2015-00799)
- Crafoord Foundation
- Skåne Regional Council
- The Königska Foundation
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Life Sciences › Neuroscience › Neurology › Transcranial Magnetic Stimulation Studies
- Keywords
- racemic ketamine, electroconvulsive therapy, major depressive disorder, antidepressant treatment, remission, relapse, treatment-emergent adverse events, amnesia, inpatient depression treatment, non-inferiority
- MeSH terms
- Adolescent, Adult, Aged, Aged, 80 and over, Antidepressive Agents, Major Depressive Disorder, Electroconvulsive Therapy, Humans, Ketamine, Middle Aged, Treatment Outcome, Young Adult, Depressive Disorder, Treatment-Resistant
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.